Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Working Group Debate Kicks Off toward Realizing New Ryukaikon Proposal
February 12, 2016
- MHLW Sends Alert on Kids’ Accidental Ingestion of Psychotropics, Other Drugs
February 10, 2016
- Frequency of Drug Price Revisions to Be Discussed by Chuikyo: Govt
February 8, 2016
- MHLW Panel Supports Pain Indication for Cymbalta by Majority Vote
February 8, 2016
- Hep B Vaccines to Join Public Immunization Program in October
February 8, 2016
- Japan, EU to Expand GMP MRA to Cover Europe; Types of Products Covered Might also Be Expanded
February 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for January
February 5, 2016
- MHLW Won’t Rule Out Single-Patient Humanitarian Trials: Official
February 5, 2016
- Council OKs Public Knowledge-Based Application for Capecitabine as Adjuvant Chemotherapy for Rectal Cancer
February 5, 2016
- Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation
February 4, 2016
- NCC, PMDA Forge Comprehensive Collaboration Pact
February 3, 2016
- MHLW Panel Backs Approval of Novartis’s Melanoma Drugs
February 2, 2016
- MHLW Allows Shipment of Kaketsuken’s Hep A, B Vaccines
February 2, 2016
- Chuikyo Reps Want Price-Based Penalty Added to Supplementary Opinions for FY2016 Reform Proposal, MHLW Expresses Caution
February 1, 2016
- Govt Says It’s “Not Recommending” Research-Driven Makers to Become Generic Makers, It’s One Option
February 1, 2016
- MHLW Sends Alert on Opdivo’s Fulminant Type 1 Diabetes Risk
February 1, 2016
- Suspended-but-Shipped Drugs Should Face 20% Price Cut, Chuikyo Member Says amid Kaketsuken Fuss
January 28, 2016
- MHLW in Final Stages of Study Aimed at Drafting Guidelines on Nucleic Acid Therapeutics; Final Report Due Out FY2016-End
January 28, 2016
- “Huge-Seller” Re-Pricing Created due to Drugs with Huge Financial Impact: Govt
January 27, 2016
- New Basic Guidelines for Hepatitis Measures to Promote Drug Discovery for Hep B
January 27, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…